Back
Dassault Systèmes to buy ArisGlobal for up to $2 billion to strengthen AI offering

Dassault Systèmes to buy ArisGlobal for up to $2 billion to strengthen AI offering

Nordic Capital said the sale marks a full exit from ArisGlobal, which serves more than 200 life sciences customers and is expected to generate about $175 million in 2026 revenue.

Fact Check
Every element of the claim is verified. The official Nordic Capital press release confirms it is a full exit and that ArisGlobal serves 200+ life sciences customers with ~$175M expected 2026 revenue. The WSJ article confirms the up-to-$2 billion acquisition price by Dassault Systèmes ($1.8B cash plus up to $200M contingent on AI revenue targets). Reuters independently corroborated the ~$2 billion figure and the parties involved.
    Reference: 123
Summary

Dassault Systèmes has agreed to acquire Nordic Capital’s ArisGlobal, a U.S. supplier of software to the life sciences industry, for up to $2 billion as it looks to strengthen its artificial-intelligence offering. The French software company said it will pay about $1.8 billion in cash at closing and up to $200 million in additional payments linked to AI-related revenue targets. Nordic Capital said the transaction represents a full exit from ArisGlobal and caps an investment period that began in 2019 and was followed by a further investment in 2021. ArisGlobal, founded in 1989 and headquartered in Waltham, Massachusetts, provides regulatory, safety and quality software through its cloud-native LifeSphere platform and says it serves more than 200 life sciences companies, CROs and government health authorities worldwide. The company said it processes more than 12 million safety cases annually, counts half of the world’s top 50 biopharma companies among its customers and is expected to generate approximately $175 million in revenue in 2026. The deal is expected to close in the second half of 2026, subject to customary regulatory approvals.

Terms & Concepts
  • cloud-native: Software built to run in modern cloud environments, allowing easier scaling, updates and remote delivery.
  • pharmacovigilance: The monitoring and management of drug safety, including the reporting and analysis of adverse events.
  • AI-related revenue targets: Performance goals tied to sales generated from artificial-intelligence products or services.